share_log

Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37

Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37

豐業銀行維持Castle Biosciences行業跑贏大盤,將目標股價上調至37美元
Benzinga ·  03/02 01:14

Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and raises the price target from $33 to $37.

豐業銀行分析師成智南維持Castle Biosciences(納斯達克股票代碼:CSTL)的板塊跑贏大盤,並將目標股價從33美元上調至37美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論